After being converted into NAD in the body, it exerts a lipid-lowering effect, which can reduce the levels of total cholesterol (TC), low-density lipoprotein (LDL-C) and triglycerides (TC), and increase the level of high-density lipoprotein (HDL-C). It can also reduce the serum levels of apolipoprotein B-100 (ApoB), most very low-density lipoprotein (VLDL), some LDL and lipoprotein a [Lp(a)].

Relaxes vascular smooth muscle, activates guanylate cyclase by releasing nitric oxide (NO), increases cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby dilating peripheral arteries and veins, reducing preload and afterload, increasing coronary artery perfusion, reducing myocardial oxygen consumption, and relieving angina pectoris.

Selective α1 receptor blockers can reduce peripheral vascular resistance and have a lowering effect on both systolic and diastolic blood pressure; they have the effect of relaxing bladder and prostate smooth muscles and can relieve symptoms of dysuria caused by benign prostatic hypertrophy.

This product is a selective α1 receptor blocker that can reduce peripheral vascular resistance and has a lowering effect on both systolic and diastolic blood pressure; it has the effect of relaxing bladder and prostate smooth muscles and can relieve symptoms of dysuria caused by benign prostatic hypertrophy.